Compugen Ltd. (TLV:CGEN)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 756.07M +63.2% |
| Revenue (ttm) | 229.40M +163.4% |
| Net Income | 110.05M |
| EPS | 1.17 |
| Shares Out | n/a |
| PE Ratio | 6.87 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,840 |
| Average Volume | 62,198 |
| Open | 826.80 |
| Previous Close | 826.80 |
| Day's Range | 795.80 - 826.80 |
| 52-Week Range | 435.00 - 924.00 |
| Beta | 2.80 |
| RSI | 53.63 |
| Earnings Date | May 18, 2026 |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T... [Read more]
News
Compugen Transcript: Stifel 2026 Targeted Oncology Virtual Forum
AI-driven immuno-oncology discovery has led to a robust pipeline, including COM701 in pivotal ovarian cancer trials, GS-0321 in partnership with Gilead, and rilvegostomig with AstraZeneca in 11 phase III studies. Recent monetization and milestones provide financial runway into 2029.
Compugen files $400M mixed securities shelf
16:04 EDT Compugen (CGEN) files $400M mixed securities shelf
Compugen Q1 Earnings Call Highlights
Compugen NASDAQ: CGEN said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company ...
Compugen Earnings Call Transcript: Q1 2026
Q1 2026 saw continued clinical and financial progress, with COM701 and partnered assets advancing in trials and a strong cash position supporting operations into 2029. Interim MAIA-ovarian trial data is expected in Q1 2027, and new rilvegostomig data will be presented at ASCO.
Compugen Earnings release: Q1 2026
Compugen released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
Compugen Registration statement: Registration filing
Compugen filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
Compugen reports Q1 EPS (8c) vs. (8c) last year
Reports Q1 revenue $2.2M vs. $2.3M last year. Compugen (CGEN) expects that its cash and cash-related balances will be sufficient to fund its operating plans into 2029. The company has…
Options Volatility and Implied Earnings Moves Today, May 18, 2026
Today, several major companies are expected to report earnings: Baidu (BIDU), Compugen (CGEN), Sachem Capital (SACH), Niu Technologies (NIU), Gossamer Bio (GOSS), Duos Technologies Group (DUOT), Yalla...
Compugen Reports First Quarter 2026 Results
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvegostomig acr...
Compugen Slides: Corporate presentation
Compugen has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, to...
Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/M...
Compugen Transcript: 25th Annual Needham Virtual Healthcare Conference
The company showcased its AI-driven immune-oncology pipeline, highlighting COM701 and rilvegostomig, with major partnerships and robust financials. Key trials target platinum-sensitive ovarian cancer and innovative bispecific antibody strategies, with pivotal data expected from 2027 onward.
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...
Compugen initiated with a Buy at Lake Street
Lake Street analyst Chad Messer initiated coverage of Compugen (CGEN) with a Buy rating and $6 price target. After high-profile Phase 3 failures from Roche (RHHBY), Merck (MRK), Gilead (GILD),…
Compugen Slides: Corporate presentation
Compugen has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Compugen Transcript: Leerink Global Healthcare Conference 2026
AstraZeneca's rilvegostomig is being tested in 11 phase III trials, leveraging a bispecific, Fc-reduced format and novel biomarker-driven combinations, with key readouts expected after 2027. COM701 is being evaluated in platinum-sensitive ovarian cancer, and an IL-18BP program with Gilead is advancing in phase I.
Compugen Earnings Call Transcript: Q4 2025
Cash runway extended into 2029 after a $65M AstraZeneca deal, with strong 2025 revenue growth and a shift to net profitability. Key clinical programs advanced globally, with major data readouts expected in 2027 and significant milestone potential from partnerships.
Compugen Annual report: Q4 2025
Compugen has published its Q4 2025 annual report on March 2, 2026.
Compugen Earnings release: Q4 2025
Compugen released its Q4 2025 earnings on March 2, 2026, summarizing the period's financial results.
Compugen reports Q4 EPS 60c vs. (7c) last year
Reports Q4 revenue $67.3M vs. $1.5M last year. “We delivered important progress in 2025, highlighted by the extension of our cash runway into 2029 through a non-dilutive monetization agreement with…
Compugen Reports Fourth Quarter and Full Year 2025 Results
Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029 Enhanced leaders...
Compugen Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
COM701 is advancing in a randomized trial for platinum-sensitive ovarian cancer, aiming to extend progression-free survival, with interim data expected in Q1 2027. Partnerships with AstraZeneca and Gilead provide financial stability and support a robust early pipeline focused on novel immuno-oncology targets.
Compugen to Participate in Upcoming Investor Conferences
HOLON, Israel, Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/...
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
HOLON, Israel, Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI...